Cycurion, Inc. (CYCU): Entry into a Material Definitive Agreement
Cycurion, Inc. (CYCU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Series H Conversion Inducement and Exchange Agreements On October 29, 2026, Cycurion, Inc., a Delaware corporation (the “Company”), entered into separate Series H Convertible Preferred Stock Conversion Inducement and Exchange
How this was made
The 30-second read
Why it matters
The conversion will increase common share count, potentially diluting existing shareholders and creating short‑term price pressure, but also removes preferred dividend obligations.
Market read
Primary disclosure of a material definitive agreement that could affect CYCU's share structure and price dynamics.
What to watch
Potential tax implications for holders and the timing of Nasdaq minimum price compliance could delay conversions.
Background
Cycurion filed an 8‑K detailing Series H Convertible Preferred Stock Conversion Inducement and Exchange Agreements with two holders, outlining exchange price, ownership limits, and resale restrictions.
Ticker impact
The 8‑K reports Cycurion's entry into conversion agreements allowing holders to exchange Series H preferred for common shares at $2.70, potentially diluting existing shareholders.
likely pressure as the market prices in dilution from the conversion.
The filing details the exchange terms, ownership caps, and resale restrictions, indicating a material change to share structure.
Market effects
May affect other small‑cap biotech and fintech firms using convertible preferred structures.
Limited to U.S. over‑the‑counter markets where CYCU trades.
Low, as the company is micro‑cap with niche exposure.
Counterpoint
If the conversion proceeds smoothly, the added liquidity could support the stock price rather than depress it.
Key entities
- companyCycurion, Inc.
Issuer of the Series H Convertible Preferred Stock.
- holderObsidian Associates, LLC
Holder of 618.75 Series H preferred shares.
- holderM2B Funding Corp.
Holder of 952.70 Series H preferred shares.
